Biopharma mergers and acquisitions reached $84 billion in the first quarter of 2026, the strongest start since 2019, as drugmakers accelerate dealmaking to offset upcoming patent expirations.

Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their ...

While several major biotech companies are laying off employees by the hundreds, one is dropping billions in acquisitions.

Regulators consider end to compounding of GLP-1s; RFK Jr. appeals court decision blocking changes to vaccine schedule; FDA ...

Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun ...

Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the best biotech penny stocks to buy in 2026. On March 23, Arbutus ...

Efforts to make customized medicines at scale have hit commercial and regulatory roadblocks. Julia Vintarello is trying again ...

Sutro Biopharma, Inc. (NASDAQ:STRO) is one of the best performing small cap stocks so far in 2026. Citizens lifted the price ...

Sutro Biopharma underwent major restructuring, including management changes and layoffs. Read why I rate STRO stock a Strong ...

Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a ...

Cue Biopharma named Shao-Lee Lin as its chief executive officer. Lin succeeds Lucinda Warren, who held the CEO role on an interim basis. Lin was previously founder and CEO of biotechnology company ...

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseasesCue Biopharma plans to ...